[Neoadjuvant chemoradiation therapy for locally advanced rectal cancer].
Not only the improvement of overall survival, but also the control of local recurrence, a unique type of recurrence, is an important issue in the treatment of advanced local rectal cancer. Total mesorectal excision is internationally accepted to be a standard procedure that lowers the rate of local recurrence. In 1999, the National Institutes of Health in the United States recommended "resection plus postoperative chemoradiotherapy" as the standard treatment for pathological stage II and III rectal cancer. In Japan, however, few large clinical trials of adjuvant radiotherapy have been performed because the rate of local recurrence in patients undergoing surgery alone is lower than that in Western countries. Multicenter, randomized, controlled studies with total mesorectal excision as a control are ongoing in Japan, and the results are awaited. We describe the current status of adjuvant chemoradiotherapy for advanced local rectal cancer in Japan and other countries, along with a review of the literature.
Sato
Takeo
T
Dept. of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Ozawa
Heita
H
Kisyu
Kazuhiko
K
Kumamoto
Hiroshi
H
Nakamura
Takatoshi
T
Onozato
Wataru
W
Yamanashi
Takahiro
T
Kokuba
Yukihito
Y
Ihara
Atsushi
A
Watanabe
Masahiko
M
D017024:Chemotherapy, Adjuvant / Q000379:methods*; D006801:Humans; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy / Q000379:methods*; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000628:therapy*